FDA Approves First NGS-Based Liquid Biopsy Companion Diagnostic

The FDA has approved Guardant360 CDx for tumor mutation profiling in patients with any solid cancerous tumor and has also approved it as a CDx to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso (osimertinib).
Unrecognizable businessman having chest pain and heart attack

Heart Disease Biomarker Captured by New Nanoparticle Technology

The new method, called nanoproteomics, captures and measures various forms of the protein cardiac troponin I, or cTnI, a biomarker of heart damage currently used to help diagnose heart attacks and other heart diseases.

Northwell Health Releases Data on COVID-19 Antibody Testing of its Frontline Staff

More than 40,000 HCPs consented to testing with 13% (5,523) testing positive for antibodies. The positive sample pool comprised 11,468 (28.4% of positive tests) and 3,746 physicians (9.3%).
Tumor profiling assays of Foundation Medicine and Caris Life Sciences will identify abnormalities qualifying a patient for personalized cancer treatment through NCI-MATCH. [Royalty Stock Photo/Shutterstock]

TRACK Study Seeks to Develop Precision Medicine Approaches for Rare Cancers

TRACK will recruit 400 people diagnosed with any rare cancer, which is defined as incidence of six per 100,000 people, per year, in the U.S. The study will focus on cholangiocarcinoma and cancer of unknown primary due to the promise of precision approaches in these subsets.
Freenome’s artificial intelligence (AI) genomics platform

AI Predicts Patient Phenotypes that Will Develop Drug Resistance

Findings from the new study could point to methods for identifying diseases and predicting their behaviors that are faster, simpler, less expensive, and more accurate than current standard techniques.

Gene Expression Signature in Blood Can Diagnose Brain Damage in Newborn Babies

Results from the early blood tests showed that those that had poor outcomes from oxygen deprivation during birth could be predicted based on changes in the expression of 855 genes in the blood shortly after birth.
|Epic Science’s lab

It’s in the Blood

Companies are rapidly advancing liquid biopsies as the go-to technology for cancer treatment monitoring and recurrence.
FDNA has commercialized a facial recognition product called Face2Gene that uses 2D images for the diagnoses of rare diseases.

3D Facial Imaging Tool Can Help Diagnose Genetic Diseases

A computer-based facial analysis tool and 3D image database could help children with genetic conditions to get a quicker and more accurate diagnosis, suggests...
Coronavirus, artwork

Oxford Nanopore to Supply U.K. with 450K LamPORE COVID-19 Tests

LamPORE uses Oxford Nanopore’s sequencing technology to precisely identify amplified sections of the SARS-CoV-2 virus, after it has been targeted and amplified using RT-LAMP, which can differentiate between actual SARS-CoV2 presence and errors that can occur during amplification.
Skin cancer, light micrograph

Low Amounts of ctDNA Can Predict Good Immunotherapy Outcome

Cancer patients who have low levels of circulating tumor (ct)DNA before starting treatment with immunotherapy are more likely to have a positive response to the treatment, according to research from the University of Toronto.
Scroll Up